4-Sep-2026
Globe Newswire (Wed, 12-Aug 7:00 AM ET)
Market Chameleon (Tue, 10-Feb 4:41 AM ET)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of September 4, 2026, STRO stock price declined to $20.07 with 124,091 million shares trading.
STRO has a beta of 2.14, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.08 to the broad based SPY ETF.
STRO has a market cap of $332.50 million. This is considered a Small Cap stock.
Last quarter Sutro Biopharma reported $10 million in Revenue and -$2.33 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.11.
In the last 3 years, STRO traded as high as $61.30 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, VXF, FESM, VTWO, VFMO.
STRO has outperformed the market in the last year with a return of +96.8%, while the SPY ETF gained +19.8%. However, in the most recent history, STRO shares have underperformed the stock market with its stock returning -30.0% in the last 3 month period and -4.6% for the last 2 week period, while SPY has returned +2.0% and +0.6%, respectively.
STRO support price is $19.38 and resistance is $21.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.